key: cord-0752077-byw8jsqv
authors: Milman, O.; Yelin, I.; Aharony, N.; Katz, R.; Herzel, E.; Ben-Tov, A.; Kuint, J.; Gazit, S.; Chodick, G.; Patalon, T.; Kishony, R.
title: SARS-CoV-2 infection risk among unvaccinated is negatively associated with community-level vaccination rates
date: 2021-03-29
journal: nan
DOI: 10.1101/2021.03.26.21254394
sha: 1e24db2a13b298a4f006a84888223a9426c0d7ae
doc_id: 752077
cord_uid: byw8jsqv

Mass vaccination has the potential to curb the current COVID-19 pandemic by protecting vaccinees from the disease and possibly lowering the chance of transmission to unvaccinated individuals. The high effectiveness of the widely-administered BNT162b vaccine in preventing not only the disease but also infection suggests a potential for a population-level effect, critical for disease eradication. However, this putative effect is difficult to observe, especially in light of highly fluctuating spatio-temporal epidemic dynamics. Here, analyzing vaccination records and test results collected during a rapid vaccine rollout for a large population from 223 geographically defined communities, we find that the rates of vaccination in each community are highly correlated with a later decline in infections among a cohort of under 16 years old which are unvaccinated. These results provide observational evidence that vaccination not only protects individual vaccinees but also provides cross-protection to unvaccinated individuals in the community.

highly correlated with a later decline in infections among a cohort of under 16 years old which are unvaccinated. These results provide observational evidence that vaccination not only protects individual vaccinees but also provides cross-protection to unvaccinated individuals in the community.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 29, 2021. ; https://doi.org/10.1101/2021.03.26.21254394 doi: medRxiv preprint NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

The recently authorized Pfizer-BioNTech COVID-19 BNT162b vaccine is highly effective at preventing disease and infection at the individual level, as demonstrated in the clinical trial, as well as in real-world vaccination campaigns [1] [2] [3] [4] . Moreover, among vaccinees infected with SARS-CoV-2, a lower viral load was observed 5 . Reduced infection and viral load suggest reduced transmission. However, vaccination could, in principle, also increase transmission due to behavioral effects; as vaccinees may not quarantine after contacting a COVID-19 patient, or be less mindful of social distancing measures 6 . It is therefore unclear whether, overall, vaccination reduces transmission, thereby conferring protection to those who are unvaccinated or cannot currently be vaccinated, for example individuals below 16 years old, or individuals with a poor immune response 4,7-9 . However, since even in absence of vaccination the basic reproduction number varies with sociobehavioral and environmental factors, and global disease rates represent both vaccinated and unvaccinated individuals, it has proven challenging to determine the effect of vaccination on community-level SARS-CoV-2 transmission 10-12 .

The rapid vaccine rollout in Israel, initiated on December 19, 2020 and covering almost 50% of the population within 9 weeks, presents a unique opportunity to test these questions using real-world data. Capitalizing on differences in vaccination rates among geographically distinct communities, and on the availability of an unvaccinated bystander cohort of individuals below 16 for whom the vaccine is not authorized, we asked whether and to what extent the fraction of CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 29, 2021. ; https://doi.org/10.1101/2021.03.26.21254394 doi: medRxiv preprint (IQR: 5.5%) for the large and small clusters, respectively. As both vaccination and natural infection may render individuals immunized, thereby possibly conferring protection on unvaccinated individuals, high infection rates may mask the effect of vaccination-induced immunity. We therefore chose to focus on the community cluster with lower positive rates, which will allow us to identify vaccination effects while minimizing the potential confounding effect of natural immunization.

To control for the spatio-temporally dynamic nature of the epidemic, we focused on relative changes in positive test rates within each community at fixed time intervals, thus accounting for global temporal patterns as well as for intrinsic differences among communities. First, for each community, the mean cumulative fraction of patients inoculated with the first dose of the vaccine was calculated at three distinct intervals for individuals 16-50 years old, which presumably represent the population likely to interact with the bystander unvaccinated cohort of under 16 years old ( Fig. 1a ; V 1 , V 2 , and V 3 ). Then, for each such vaccination time interval, a corresponding time-shifted testing interval was defined with a delay of 35 days, to allow for the putative immunization of vaccinees to take effect ( Fig. 1a,b ). For these three testing intervals, the positive rate among the unvaccinated bystander cohort was calculated ( Fig. 1b , P 1 , P 2 , and P 3 ). Comparing periods 1 and 2, and periods 2 and 3, we then focused on the relationship between the change in positive rate of the unvaccinated cohort (P 2 /P 1 , P 3 /P 2 ) and the change in Fig. 1c,d) . to -0.9], P-value<10 -3 ). The correlations remained strong when the upper age limit for measuring vaccination rate was lowered to 40 (P-value<10 -4 for both time interval comparisons) or increased to 60 (P-value<10 -4 for intervals 1 and 2, and P-value<10 -3 for intervals 2 and 3), but became insignificant when the age limit was increased beyond 70, possibly reflecting less frequent contacts between the vaccinated and unvaccinated cohorts. Taken together, our . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Our study has several important limitations. First, beyond vaccine-based immunity, infections of unvaccinated could also be affected by naturally acquired immunity. While we minimize this confounding factor by focusing on communities with low cumulative prior infections, future studies may more directly control for this effect, for example by including seroprevalence data.

Second, individual behavior and public policy guidelines may correlate with vaccination rates, and affect the infection potential of the unvaccinated group. Third, the proportion between the measured positive test rate and the actual infection rate could be different in each community and may also vary with time. Using the logarithmic derivatives [log(P 2 /P 1 ), or log(P 3 /P 2 )], our analysis accounts for the possibility of different proportions between the infection rate and the positive rate in each community as well as for the possibility that this proportion changes uniformly with time, but it cannot account for the possibility that these proportions change over time in different ways for different communities. Finally, our study population is limited to MHS members, only partially representing the overall population for each community.

In this study, we identified a strong negative association between vaccination rate at the community level and the risk of infection for unvaccinated members of the community. We find that higher vaccination rates were associated with a later lower infection rate among the unvaccinated cohort. While the observed vaccine-associated protection of unvaccinated is encouraging, further studies are required to understand whether and how it might support the prospect of herd immunity and disease eradication. Vaccination and testing intervals. We defined 3 consecutive three-weeks testing intervals between January 3rd 2021 and March 6th. For each of these three testing intervals and each community, the positive test rate among unvaccinated individuals below 16 years old was calculated (P 1 , P 2 and P 3 ), and their standard errors were evaluated assuming poisson statistics.

MHS members were excluded from this calculation if they were tested more than 20 times (to avoid patients participating in extensive surveys). In addition, for each MHS member, any test following a positive test was excluded from this calculation. To account for the expected time post first dose for a vaccinee to acquire immunity and to potentially prevent further infections, each three-week testing interval was matched with a corresponding three-week vaccination is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 29, 2021. ; https://doi.org/10.1101/2021.03.26.21254394 doi: medRxiv preprint Correlation analysis. For each two consecutive three-weeks intervals (intervals 1 and 2, and intervals 2 and 3), a linear fit was performed on the log ratio of the positive rate and the change in vaccination using MATLAB's glmfit built-in function (Y=log(P 2 /P 1 ) and X=V 2 -V 1 for intervals 1 and 2; Y=log(P 3 /P 2 ) and X=V 3 -V 2 for intervals 2 and 3). For each of the two linear fits, the slope P-value was calculated as the fraction of smaller or equal slopes calculated in 10,000 X-Y permutation bootstrapping simulations.

Ethics committee approval. The study protocol was approved by the ethics committee of Maccabi Healthcare Services, Tel-Aviv, Israel. The IRB includes an exempt from informed consent.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Data is binned into two-weeks periods. Cities are clustered based on euclidean distance among their positive rates, yielding two distinct clusters (dendrogram, right). The top (magenta) cluster, of 223 communities with relatively low infection rate, was chosen for analysis of vaccine effects.

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 29, 2021. ; https://doi.org/10.1101/2021.03.26.21254394 doi: medRxiv preprint

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

The effectiveness of the first dose of BNT162b2 vaccine in reducing SARS-CoV-2 infection 13-24 days after immunization: real-world evidence

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Associations of the BNT162b2 COVID-19 vaccine effectiveness with patient age and comorbidities. bioRxiv (2021)

Decreased SARS-CoV-2 viral load following vaccination

Five reasons why COVID herd immunity is probably impossible

Herd Immunity to COVID-19

Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic

COVID-19 herd immunity: where are we?

Complexity of the Basic Reproduction Number (R0)

COVID-19 seropositivity changes in asymptomatic individuals during the second and third waves of COVID-19 in Tokyo

Association of SARS-CoV-2 Seropositive Antibody Test With Risk of . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity

. CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 29, 2021. ; https://doi.org/10.1101/2021.03.26.21254394 doi: medRxiv preprint